Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1955 2
1963 1
1969 1
1974 4
1975 3
1976 3
1977 9
1978 11
1979 18
1980 8
1981 24
1982 35
1983 45
1984 42
1985 83
1986 95
1987 81
1988 88
1989 161
1990 159
1991 189
1992 175
1993 205
1994 283
1995 312
1996 363
1997 444
1998 526
1999 517
2000 651
2001 685
2002 841
2003 929
2004 992
2005 1041
2006 1169
2007 1147
2008 1192
2009 1267
2010 1458
2011 1481
2012 1604
2013 1753
2014 1784
2015 1914
2016 2019
2017 2024
2018 2138
2019 2207
2020 1722
2021 402
Text availability
Article attribute
Article type
Publication date

Search Results

31,095 results
Results by year
Filters applied: . Clear all
Page 1
Alzheimer's disease: clinical trials and drug development.
Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Mangialasche F, et al. Lancet Neurol. 2010 Jul;9(7):702-16. doi: 10.1016/S1474-4422(10)70119-8. Lancet Neurol. 2010. PMID: 20610346 Review.
Alzheimer's disease is the most common cause of dementia in elderly people. ...Several promising randomised controlled trials are ongoing, and the increased collaboration between pharmaceutical companies, basic researchers, and clinical research
Alzheimer's disease is the most common cause of dementia in elderly people. ...Several promising randomised cont
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. Veitch DP, et al. Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Alzheimers Dement. 2019. PMID: 30321505 Review.
INTRODUCTION: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ...These findings guided the development of novel biomarkers and sugge …
INTRODUCTION: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for …
Physical activity can improve cognition in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Du Z, Li Y, Li J, Zhou C, Li F, Yang X. Du Z, et al. Clin Interv Aging. 2018 Sep 4;13:1593-1603. doi: 10.2147/CIA.S169565. eCollection 2018. Clin Interv Aging. 2018. PMID: 30233156 Free PMC article. Review.
BACKGROUND/OBJECTIVE: Alzheimer's disease (AD) is mainly characterized by decline of cognitive functions such as memory and learning, which has a high prevalence and poor drug efficacy in treatment regimes. A systematic review and meta-analysis of randomiz
BACKGROUND/OBJECTIVE: Alzheimer's disease (AD) is mainly characterized by decline of cognitive functions such as memory …
Stem Cell Therapy for Alzheimer's Disease: A Review of Recent Clinical Trials.
Kang JM, Yeon BK, Cho SJ, Suh YH. Kang JM, et al. J Alzheimers Dis. 2016 Oct 4;54(3):879-889. doi: 10.3233/JAD-160406. J Alzheimers Dis. 2016. PMID: 27567851 Review.
Stem cell therapy has been noted to be a disease-modifying treatment for Alzheimer's disease (AD). After the failure to develop new drugs for AD, the number of studies on stem cells, such as mesenchymal stem cells (MSCs) and neural stem cells (NSCs), h …
Stem cell therapy has been noted to be a disease-modifying treatment for Alzheimer's disease (AD). After the fai …
Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis.
Orgeta V, Tabet N, Nilforooshan R, Howard R. Orgeta V, et al. J Alzheimers Dis. 2017;58(3):725-733. doi: 10.3233/JAD-161247. J Alzheimers Dis. 2017. PMID: 28505970 Free PMC article. Review.
BACKGROUND: Depression is common in people with Alzheimer's disease (AD) affecting overall outcomes and decreasing quality of life. Although depression in AD is primarily treated with antidepressants, there are few randomized controlled trials (RCTs) a …
BACKGROUND: Depression is common in people with Alzheimer's disease (AD) affecting overall outcomes and decreasing qual …
Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
Yang G, Wang Y, Tian J, Liu JP. Yang G, et al. PLoS One. 2013 Sep 23;8(9):e74916. doi: 10.1371/journal.pone.0074916. eCollection 2013. PLoS One. 2013. PMID: 24086396 Free PMC article. Review.
BACKGROUND: Huperzine A is a Chinese herb extract used for Alzheimer's disease. We conducted this review to evaluate the beneficial and harmful effect of Huperzine A for treatment of Alzheimer's disease. METHODS: We searched for random
BACKGROUND: Huperzine A is a Chinese herb extract used for Alzheimer's disease. We conducted this review to evaluate th …
Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
Cummings J, Ritter A, Zhong K. Cummings J, et al. J Alzheimers Dis. 2018;64(s1):S3-S22. doi: 10.3233/JAD-179901. J Alzheimers Dis. 2018. PMID: 29562511 Free PMC article. Review.
Alzheimer's disease (AD) has no currently approved disease-modifying therapies (DMTs), and treatments to prevent, delay the onset, or slow the progression are urgently needed. ...Biomarkers are critical in trials of DMTs, assisting in participant chara
Alzheimer's disease (AD) has no currently approved disease-modifying therapies (DMTs), and treatments to prevent
Neuroscience: Alzheimer's disease.
Mucke L. Mucke L. Nature. 2009 Oct 15;461(7266):895-7. doi: 10.1038/461895a. Nature. 2009. PMID: 19829367 No abstract available.
Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.
Blanco-Silvente L, Castells X, Saez M, Barceló MA, Garre-Olmo J, Vilalta-Franch J, Capellà D. Blanco-Silvente L, et al. Int J Neuropsychopharmacol. 2017 Jul 1;20(7):519-528. doi: 10.1093/ijnp/pyx012. Int J Neuropsychopharmacol. 2017. PMID: 28201726 Free PMC article. Review.
BACKGROUND: We investigated the effect of cholinesterase inhibitors on all-cause discontinuation, efficacy and safety, and the effects of study design-, intervention-, and patient-related covariates on the risk-benefit of cholinesterase inhibitors for Alzheimer's
BACKGROUND: We investigated the effect of cholinesterase inhibitors on all-cause discontinuation, efficacy and safety, and the effects of st …
Different durations of cognitive stimulation therapy for Alzheimer's disease: a systematic review and meta-analysis.
Chen J, Duan Y, Li H, Lu L, Liu J, Tang C. Chen J, et al. Clin Interv Aging. 2019 Jul 12;14:1243-1254. doi: 10.2147/CIA.S210062. eCollection 2019. Clin Interv Aging. 2019. PMID: 31371930 Free PMC article.
OBJECTIVE: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of cognitive stimulation therapy (CST) of different durations for Alzheimer's disease (AD). ...
OBJECTIVE: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of cogn …
31,095 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page